186 related articles for article (PubMed ID: 35301276)
21. Association between immunoglobulin heavy-chain variable region mutational status and isolated favorable baseline genomic aberrations in chronic lymphocytic leukemia.
Sandoval-Sus JD; Chavez JC; Dalia S; Naqvi SMH; Talati C; Nodzon L; Kharfan-Dabaja MA; Pinilla-Ibarz J
Leuk Lymphoma; 2018 Jan; 59(1):59-68. PubMed ID: 28641468
[TBL] [Abstract][Full Text] [Related]
22. Genome-wide DNA methylation profiling integrated with gene expression profiling identifies
Rani L; Mathur N; Gupta R; Gogia A; Kaur G; Dhanjal JK; Sundar D; Kumar L; Sharma A
Clin Epigenetics; 2017; 9():57. PubMed ID: 28572861
[TBL] [Abstract][Full Text] [Related]
23. IGLV3-21R110 identifies an aggressive biological subtype of chronic lymphocytic leukemia with intermediate epigenetics.
Nadeu F; Royo R; Clot G; Duran-Ferrer M; Navarro A; Martín S; Lu J; Zenz T; Baumann T; Jares P; Puente XS; Martín-Subero JI; Delgado J; Campo E
Blood; 2021 May; 137(21):2935-2946. PubMed ID: 33211804
[TBL] [Abstract][Full Text] [Related]
24. Biomarkers in chronic lymphocytic leukemia: Clinical applications and prognostic markers.
Amaya-Chanaga CI; Rassenti LZ
Best Pract Res Clin Haematol; 2016 Mar; 29(1):79-89. PubMed ID: 27742074
[TBL] [Abstract][Full Text] [Related]
25. Should IGHV status and FISH testing be performed in all CLL patients at diagnosis? A systematic review and meta-analysis.
Parikh SA; Strati P; Tsang M; West CP; Shanafelt TD
Blood; 2016 Apr; 127(14):1752-60. PubMed ID: 26841802
[TBL] [Abstract][Full Text] [Related]
26. Do biologic parameters affect the time to first treatment of clinical monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia Rai stage 0? Results of a prospective analysis.
Molica S; Giannarelli D; Levato L; Gentile M; Mirabelli R; Morabito F
Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):e55-60. PubMed ID: 25445470
[TBL] [Abstract][Full Text] [Related]
27. The Biology of Chronic Lymphocytic Leukemia: Diagnostic and Prognostic Implications.
Moia R; Patriarca A; Schipani M; Gaidano G
Cancer J; 2021 Jul-Aug 01; 27(4):266-274. PubMed ID: 34398553
[TBL] [Abstract][Full Text] [Related]
28. Chronic lymphocytic leukemia (CLL)-Then and now.
Rai KR; Jain P
Am J Hematol; 2016 Mar; 91(3):330-40. PubMed ID: 26690614
[TBL] [Abstract][Full Text] [Related]
29. IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemia.
Bulian P; Rossi D; Forconi F; Del Poeta G; Bertoni F; Zucca E; Montillo M; Pozzato G; D'Arena G; Efremov DG; Marasca R; Lauria F; Gaidano G; Gattei V; Laurenti L
J Transl Med; 2012 Jan; 10():18. PubMed ID: 22289136
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trials.
Soumerai JD; Ni A; Xing G; Huang J; Furman RR; Jones J; Sharman JP; Hallek M; Adewoye AH; Dubowy R; Dreiling L; Zelenetz AD
Leuk Lymphoma; 2019 Jun; 60(6):1438-1446. PubMed ID: 30407886
[TBL] [Abstract][Full Text] [Related]
31. Reasons for initiation of treatment and predictors of response for patients with Rai stage 0/1 chronic lymphocytic leukemia (CLL) receiving first-line therapy: an analysis of the Connect
Flowers CR; Nabhan C; Kay NE; Mato A; Lamanna N; Farber CM; Davids MS; Kiselev P; Swern AS; Sullivan K; Flick ED; Sharman JP
Leuk Lymphoma; 2018 Oct; 59(10):2327-2335. PubMed ID: 29415595
[TBL] [Abstract][Full Text] [Related]
32. Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial.
Bühler A; Wendtner CM; Kipps TJ; Rassenti L; Fraser GA; Michallet AS; Hillmen P; Dürig J; Gregory SA; Kalaycio M; Aurran-Schleinitz T; Trentin L; Gribben JG; Chanan-Khan A; Purse B; Zhang J; De Bedout S; Mei J; Hallek M; Stilgenbauer S
Blood Cancer J; 2016 Mar; 6(3):e404. PubMed ID: 26967821
[TBL] [Abstract][Full Text] [Related]
33. Prognostication of DNA Damage Response Protein Expression Patterns in Chronic Lymphocytic Leukemia.
Griffen TL; Hoff FW; Qiu Y; Burger J; Wierda W; Kornblau SM
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982555
[TBL] [Abstract][Full Text] [Related]
34. Chronic lymphocytic leukemia: a clinical and molecular heterogenous disease.
Rodríguez-Vicente AE; Díaz MG; Hernández-Rivas JM
Cancer Genet; 2013 Mar; 206(3):49-62. PubMed ID: 23531595
[TBL] [Abstract][Full Text] [Related]
35. Molecular biomarkers in chronic lymphocytic leukemia.
Malek S
Adv Exp Med Biol; 2013; 792():193-214. PubMed ID: 24014298
[TBL] [Abstract][Full Text] [Related]
36. Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.
Maddocks KJ; Ruppert AS; Lozanski G; Heerema NA; Zhao W; Abruzzo L; Lozanski A; Davis M; Gordon A; Smith LL; Mantel R; Jones JA; Flynn JM; Jaglowski SM; Andritsos LA; Awan F; Blum KA; Grever MR; Johnson AJ; Byrd JC; Woyach JA
JAMA Oncol; 2015 Apr; 1(1):80-7. PubMed ID: 26182309
[TBL] [Abstract][Full Text] [Related]
37. The Light Chain IgLV3-21 Defines a New Poor Prognostic Subgroup in Chronic Lymphocytic Leukemia: Results of a Multicenter Study.
Stamatopoulos B; Smith T; Crompot E; Pieters K; Clifford R; Mraz M; Robbe P; Burns A; Timbs A; Bruce D; Hillmen P; Meuleman N; Mineur P; Firescu R; Maerevoet M; De Wilde V; Efira A; Philippé J; Verhasselt B; Offner F; Sims D; Heger A; Dreau H; Schuh A
Clin Cancer Res; 2018 Oct; 24(20):5048-5057. PubMed ID: 29945996
[No Abstract] [Full Text] [Related]
38. Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib.
Guo A; Lu P; Galanina N; Nabhan C; Smith SM; Coleman M; Wang YL
Oncotarget; 2016 Jan; 7(4):4598-610. PubMed ID: 26717038
[TBL] [Abstract][Full Text] [Related]
39. Genetic mutations in chronic lymphocytic leukemia: impact on clinical treatment.
Condoluci A; Rossi D
Expert Rev Hematol; 2019 Feb; 12(2):89-98. PubMed ID: 30686074
[TBL] [Abstract][Full Text] [Related]
40. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data.
International CLL-IPI working group
Lancet Oncol; 2016 Jun; 17(6):779-790. PubMed ID: 27185642
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]